The Effect of HPV Vaccine on Menstrual Cycle in Women of Reproductive Age

Sponsor

Sun Yat-sen University (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05838157

Collaborator

(none)

600

Enrollment

Location

19.9

Anticipated Duration (Months)

30.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Cervical cancer is one of the most common cancer in women, making it the fourth largest cause of female cancer mortality worldwide. High-risk HPV types (hrHPV) continuous infection is the main cause of the premalignant and malignant lesions of the cervix. The most effective primary prevention of cervical cancer is administration HPV vaccines. There are three prophylactic HPV vaccines including bivalent HPV (2vHPV)， quadrivalent HPV vaccine (4vHPV)，9-valent HPV vaccine (9vHPV) currently. With the widespread of HPV vaccination， the cases related to abnormal menstrual cycle or menstrual irregularities has gradually increased in the Vaccine Adverse Event Reporting System, also the number of reports and studies were increasing. We designed this study to evaluate the statistical association of HPV vaccine and changes in menstrual cycle or menstrual irregularities、amenorrhea. And detect the signal of premature ovarian insufficiency (POI) and related events of three HPV vaccines, and to provide evidence for the safety of HPV vaccines based on the data mining and signal detection method. The research data was obtained from prospective self- developed questionnaire. Before-after study was applied in this study, investigators collect the menstrual cycle data of subjects by the questionnaire and qualitatively interview were taken. The control group is before vaccination, HPV vaccination is Intervention group.

Condition or Disease	Intervention/Treatment	Phase
Menstrual Disorder Premature Ovarian Failure	Biological: prophylactic HPV vaccine(bivalent HPV、quadrivalent HPV、9-valent HPV)

Detailed Description

High-risk HPV types (hrHPV) continuous infection is the main cause of the premalignant and malignant lesions of the cervix. The most effective primary prevention of cervical cancer is administration HPV vaccines. There are three prophylactic HPV vaccines including bivalent HPV (2vHPV)， quadrivalent HPV vaccine (4vHPV)，9-valent HPV vaccine (9vHPV) currently. With the widespread of HPV vaccination， the cases related to abnormal menstrual cycle or menstrual irregularities has gradually increased in the Vaccine Adverse Event Reporting System, also the number of reports and studies were increasing. Whereas all of the studies are retrospective and the data from passive surveillance system, meanwhile, HPV vaccines has been available in Chinese mainland less than 7 years. Especially, 9vHPV applicable range was broadened to 45 years shortly before. There are rarely prospective researches focus on the connection between HPV vaccines and menstrual disorder. We designed this prospective study to observe and evaluate the statistical association of HPV vaccine and menstrual disorder such as menstrual irregularities、amenorrhea、 hypomenorrhea or hypermenorrhea in Chinese women. And detect the signal of premature ovarian insufficiency (POI) and related events of three HPV vaccines, and to provide evidence for the safety of HPV vaccines based on the data mining and signal detection method.

The study design used self-control, We using a self-designed questionnaire collect the menstruation data of girls and women aged 16 to 40 years who receiving HPV vaccination ( including 2vHPV、4vHPV、9vHPV) in Cancer Prevention Center, Sun Yat-sen University Cancer Center during May 10th 2023 to April 30th 2023. The self-designed questionnaire contains three parts. First part includes personal basic information such as age, profession, education Level, marital or childbearing status etc. Part two there are containing health status, menstruation conditions (include menstrual cycle, menstrual period, menstrual blood volume and dysmenorrhea etc). Part three collects menstruation conditions by qualitatively interview , covers each menstrual cycle after the first dose of HPV vaccination until 3 months after the third dose .

To analyze the data, R studio statistical software was used. The general measurement data were analyzed by paired sample T test, p=0.05. Bayesian trusted Propagation neural network (BCPNN) and multi-item gamma Poisson contractor (MGPS) were used to detect the signals of POI related events and to conduct empirical Bayes data mining among ours database.

Study Design

Study Type:

Observational

Anticipated Enrollment :

600 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Research for the Effect of HPV Vaccine on Menstrual Cycle in Women of Reproductive Age

Anticipated Study Start Date :

May 4, 2023

Anticipated Primary Completion Date :

May 31, 2024

Anticipated Study Completion Date :

Dec 31, 2024

Arms and Interventions

Arm	Intervention/Treatment
Girls and women aged 16 to 40 years who receiving at least one dose of HPV vaccination Girls and women aged 16 to 40 years who receiving HPV vaccination ( including 2vHPV、4vHPV、9vHPV) in Cancer Prevention Center, Sun Yat-sen University Cancer Center during April 10th 2023 to April 30th 2023.	Biological: prophylactic HPV vaccine(bivalent HPV、quadrivalent HPV、9-valent HPV) at least one dose of prophylactic HPV vaccine including bivalent HPV (2vHPV)， quadrivalent HPV vaccine (4vHPV)，9-valent HPV vaccine (9vHPV)

Arm

Intervention/Treatment

Girls and women aged 16 to 40 years who receiving at least one dose of HPV vaccination

Girls and women aged 16 to 40 years who receiving HPV vaccination ( including 2vHPV、4vHPV、9vHPV) in Cancer Prevention Center, Sun Yat-sen University Cancer Center during April 10th 2023 to April 30th 2023.

Biological: prophylactic HPV vaccine(bivalent HPV、quadrivalent HPV、9-valent HPV)

at least one dose of prophylactic HPV vaccine including bivalent HPV (2vHPV)， quadrivalent HPV vaccine (4vHPV)，9-valent HPV vaccine (9vHPV)

Outcome Measures

Primary Outcome Measures

Frequency of the menstrual cycle [3 months after the administration of the third dose of vaccine( starts with the first dose of HPVvaccine, no less than 9 cycles)]
In 16~40 years old women , any frequency shorter than 21 days or longer than 36 days will be defined as abnormal
Duration of the menstrual cycle [3 months after the administration of the third dose of vaccine( starts with the first dose of HPVvaccine, no less than 9 cycles)]
In 16~40 years old women , any duration shorter than 3 days or longer than 7 days will be defined as abnormal
Quantity of the menstrual cycle [3 months after the administration of the third dose of vaccine( starts with the first dose of HPVvaccine, no less than 9 cycles)]
In 16~40 years old women , any quantity less than 30 ml or more than 80 ml will be defined as abnormal

Secondary Outcome Measures

Premature ovarian failure (POF) signals [3 months after the administration of the third dose of vaccine( starts with the first dose of HPVvaccine, no less than 9 cycles)]
From the first dose of the vaccine, Blood biochemical detection used to measure the levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone (P), testosterone (T) and prolactin (PRL). And Ultrasonography is used to detected changes in the endometrium after each vaccination.

Eligibility Criteria

Criteria

Ages Eligible for Study:

16 Years to 40 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Previous menstrual cycles were regular and normal
At least one vaccination of HPV vaccine

Exclusion Criteria:

Pregnancy
Breast-feeding
Record of abnormal results of HPV test/ cervical cytology/ gynecological ultrasonography
Record of medications related to menstruation
Diseases contribute to menstrual irregularities、amenorrhea such as severe anemia/ coagulation disorders/ thyroid dysfunction etc.
Participation in other clinical trials